The Latest in Psoriatic Arthritis

Rheumatology News

FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)

February 5, 2021

Rheumatology News

In head-to-head trial, two biologics differ markedly for control of psoriasis

February 4, 2021

Psoriatic Arthritis

Rheumatology News

Patients with early arthritis may need tailored treatments

February 2, 2021

Rheumatology News

Tofacitinib for RA misses the mark in safety study

February 1, 2021

Rheumatology News

Guselkumab maintains psoriasis efficacy long after discontinuation

January 26, 2021

Psoriatic Arthritis

Rheumatology News

Deucravacitinib offers biologic-like psoriasis efficacy in oral form

January 8, 2021

Psoriatic Arthritis

Rheumatology News

Osteoporosis prevalence in PsA similar to general population

January 6, 2021

Rheumatology News

EULAR recommendations define strategies to improve adherence in RMDs

January 4, 2021

Rheumatology News

COVID-19 vaccines: Safe for immunocompromised patients?

December 17, 2020

Rheumatology News

Synovial, skin gene expression differences may explain PsA treatment responses

December 11, 2020

Psoriatic Arthritis

International expert group agrees on redefining psoriasis severity

December 1, 2020

Psoriatic Arthritis

Rheumatology News

The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis

November 30, 2020

Psoriatic Arthritis

Rheumatology News

Expanded indications likely for apremilast

November 30, 2020

A Review of ACR Convergence Abstracts on Psoriatic Arthritis

November 25, 2020

Psoriatic Arthritis

Rheumatology News

TNF inhibitor–induced psoriasis treatment algorithm maintains TNF inhibitor if possible

November 25, 2020